Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Alemtuzumab

Alemtuzumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Alemtuzumab

49 trials tracked of Alemtuzumab: 10 in phase 3 or 4 and 5 with published results. The most-cited published study has 149 citations.

49Trials tracked
10Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 6 Phase 3 4 Phase 2 36 Phase 1 1 Other / NA 2
  1. Phase 3 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Completed · 149 cited
  2. Phase 3 An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab Completed · 37 cited
  3. Phase 4 Belatacept Early Steroid Withdrawal Trial Completed · 34 cited
  4. Phase 4 Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation Completed · 6 cited
  5. Phase 4 Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis Completed
  6. Phase 4 Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis Completed
Show 43 more trials
  1. Phase 4 Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients Completed
  2. Phase 4 Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Completed
  3. Phase 3 Stem Cell Transplantation for Sickle Cell Anemia Completed
  4. Phase 3 Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One Completed
  5. Phase 2 HSCT for High Risk Inherited Inborn Errors Completed
  6. Phase 2 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed
  7. Phase 2 Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  8. Phase 2 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed
  9. Phase 2 Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Completed
  10. Phase 2 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Completed
  11. Phase 2 Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia Completed
  12. Phase 2 Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Completed
  13. Phase 2 CFAR Study in Patients With Chronic Lymphocytic Leukemia Completed
  14. Phase 2 Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR Completed
  15. Phase 2 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed
  16. Phase 2 Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation Completed
  17. Phase 2 Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients Completed
  18. Phase 2 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults Completed
  19. Phase 2 Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Completed
  20. Phase 2 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia Completed
  21. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders Completed
  22. Phase 2 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Completed
  23. Phase 2 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Completed
  24. Phase 2 Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients Completed
  25. Phase 2 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia Completed
  26. Phase 2 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Completed
  27. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Completed
  28. Phase 2 Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  29. Phase 2 Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Completed
  30. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  31. Phase 2 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia Completed
  32. Phase 2 Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma Completed
  33. Phase 2 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  34. Phase 2 A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL Completed
  35. Phase 2 Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Completed
  36. Phase 2 Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Completed
  37. Phase 2 Belatacept Post Depletional Repopulation to Facilitate Tolerance Completed
  38. Phase 2 Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia Completed
  39. Phase 2 Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed
  40. Phase 2 Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia Completed
  41. Phase 1 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Completed
  42. N/A Non-Myeloablative Allogeneic Stem Cell Transplantation Completed
  43. N/A Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS
Neurology Sys. Review
Cladribine tablets reduce annualized relapse rate by 58% compared to placebo in active RRMS Cladribine tablets show promise for managing relapsing-remitting multiple sclerosis
This systematic review and network meta-analysis of 66 studies evaluated cladribine against various disease-modifying treatments for relapsi…
New data shows cladribine tablets significantly reduce relapse rates and slow disease progression in people with active relapsing-remitting …
Jul 1, 2026
Real-world cohort examines Alemtuzumab effects on bowel/bladder function and latent progressive trajectories in MS patients
Neurology Cohort
Real-world cohort examines Alemtuzumab effects on bowel/bladder function and latent progressive trajectories in MS patients Did you know MS patients hide worsening symptoms that doctors might miss for years?
This real-world cohort study involving 1,025 MS patients utilized a trajectory-based statistical approach to analyze disease progression.
Doctors might miss worsening MS symptoms for years because patients hide them, but a new method found over 11,000 hidden patterns in real-wo…
Frontiers Apr 16, 2026